Acorda Therapeutics, Inc. provided earnings guidance for the fourth quarter of 2020. For the quarter the company expected INBRIJA net revenue of approximately $9 million. For the Full year of 2020 the company expected net revenue of approximately $24 million. The Company continues to expect full year non-GAAP 2020 operating expense of $170 million to $180 million.